Acquisition boosts Sanofi's US consumer healthcare profile
December 23, 2009.
Sanofi-Aventis is to buy US consumer health company Chattem in a $1.9 bn (Euro 2.71 bn) cash deal, according to a report in the UK Financial Times. Chattem sells products such as Icy Hot cream and Selsun Blue anti-dandruff shampoo; the acquisition will provide the French company with “the ideal platform in the US consumer healthcare market,” according Sanofi boss Chris Viehbacher.
Sanofi will pay $93.50 (Euro 133.71) a share for Chattem; the offer was at a 34 per cent premium to Chattem’s closing stock price on Friday 18th December. The US company’s shares leapt 32.8 per cent to $92.94 in midday trading.
The deal is expected to close in the first quarter of 2010. Sanofi will retain Chattem’s two manufacturing plants in Tennessee, US, and also build a third.
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
Pfizer, GSK Gain ACIP Recommendations for RSV and Meningococcal Vaccines
April 18th 2025The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices voted to expand access to Pfizer’s respiratory syncytial virus vaccine Abrysvo for high-risk adults in their 50s and voted in favor of GSK’s meningococcal vaccine, Penmenvy, for streamlined adolescent protection.
